Underdosed and Underappreciated: Why Japanese Community-Acquired Pneumonia Outcomes With Ampicillin-Sulbactam May Not Translate Globally.
作者信息
Mitaka Hayato, Brade Karrine, Castillo Alyssa Y
机构信息
Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA.
Antimicrobial Stewardship Program, University of Colorado Hospital, Aurora, Colorado, USA.
出版信息
Open Forum Infect Dis. 2025 Jun 11;12(7):ofaf348. doi: 10.1093/ofid/ofaf348. eCollection 2025 Jul.
Abstract
摘要
相似文献
1
Underdosed and Underappreciated: Why Japanese Community-Acquired Pneumonia Outcomes With Ampicillin-Sulbactam May Not Translate Globally.剂量不足且未得到充分重视：为何日本使用氨苄西林-舒巴坦治疗社区获得性肺炎的结果可能无法推广至全球。
Open Forum Infect Dis. 2025 Jun 11;12(7):ofaf348. doi: 10.1093/ofid/ofaf348. eCollection 2025 Jul.
2
Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study.氨苄西林-舒巴坦与头孢曲松用于老年人社区获得性肺炎初始治疗的有效性：一项目标试验模拟研究
Open Forum Infect Dis. 2025 Mar 5;12(3):ofaf133. doi: 10.1093/ofid/ofaf133. eCollection 2025 Mar.
3
Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.氨苄西林/舒巴坦与头孢孟多治疗社区获得性肺炎的随机对照试验。
Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):293-8. doi: 10.1007/BF01974603.
4
Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.氨苄西林和舒巴坦在社区获得性肺炎患者中的群体药代动力学：肾功能损害影响的评估
Br J Clin Pharmacol. 2014 Mar;77(3):509-21. doi: 10.1111/bcp.12232.
5
A clinical comparative study of piperacillin and sulbactam/ampicillin in patients with community-acquired bacterial pneumonia.哌拉西林与舒巴坦/氨苄西林治疗社区获得性细菌性肺炎患者的临床对照研究
Intern Med. 2009;48(1):49-55. doi: 10.2169/internalmedicine.48.1614. Epub 2009 Jan 1.
6
Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia.舒巴坦/氨苄西林与亚胺培南/西司他丁治疗老年社区获得性肺炎的临床对比研究
Intern Med. 2006;45(17):995-9. doi: 10.2169/internalmedicine.45.1717. Epub 2006 Oct 2.
7
Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.氨苄西林与β-内酰胺酶抑制剂（舒巴坦/氨苄西林）治疗老年社区获得性肺炎的临床疗效
J Infect Chemother. 2003 Jun;9(2):183-6. doi: 10.1007/s10156-003-0233-y.
8
Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.氨苄西林/舒巴坦治疗老年社区获得性肺炎患者。
Infection. 2014 Feb;42(1):79-87. doi: 10.1007/s15010-013-0518-8. Epub 2013 Aug 1.
9
Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.每日4次静脉注射3克舒巴坦/氨苄西林治疗日本中重度社区获得性肺炎成人患者的疗效与安全性：一项多中心、开放标签、非对照研究
J Infect Chemother. 2015 Mar;21(3):182-8. doi: 10.1016/j.jiac.2014.11.006. Epub 2014 Nov 20.
10
An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.意大利一项关于住院社区获得性肺炎患者序贯静脉及口服阿奇霉素联合静脉注射氨苄西林/舒巴坦的研究经验。
J Chemother. 2008 Apr;20(2):225-32. doi: 10.1179/joc.2008.20.2.225.
本文引用的文献
1
Effectiveness of Ampicillin-Sulbactam Versus Ceftriaxone for the Initial Treatment of Community-Acquired Pneumonia in Older Adults: A Target Trial Emulation Study.氨苄西林-舒巴坦与头孢曲松用于老年人社区获得性肺炎初始治疗的有效性：一项目标试验模拟研究
Open Forum Infect Dis. 2025 Mar 5;12(3):ofaf133. doi: 10.1093/ofid/ofaf133. eCollection 2025 Mar.
2
Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including .氨苄西林/舒巴坦治疗包括……在内的多种细菌所致肺炎的肺药代动力学和药效学评价
Antibiotics (Basel). 2023 Feb 2;12(2):303. doi: 10.3390/antibiotics12020303.
3
Antimicrobial Susceptibility Survey of Invasive Haemophilus influenzae in the United States in 2016.2016 年美国侵袭性流感嗜血杆菌的抗菌药物敏感性调查。
Microbiol Spectr. 2022 Jun 29;10(3):e0257921. doi: 10.1128/spectrum.02579-21. Epub 2022 May 10.
4
Nationwide cross-sectional study of antimicrobial stewardship and antifungal stewardship programs in inpatient settings in Japan.日本住院环境中抗菌药物管理和抗真菌药物管理计划的全国横断面研究。
BMC Infect Dis. 2021 Apr 16;21(1):355. doi: 10.1186/s12879-021-06035-5.
5
Effects of dosing frequency on the clinical efficacy of ampicillin/sulbactam in Japanese elderly patients with pneumonia: A single-center retrospective observational study.在日本老年肺炎患者中，给药频率对氨苄西林/舒巴坦临床疗效的影响：一项单中心回顾性观察研究。
Pharmacol Res Perspect. 2021 Apr;9(2):e00746. doi: 10.1002/prp2.746.
6
Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of japanese society of chemotherapy, the japanese association for infectious diseases, and the japanese society for clinical microbiology in 2016: General view of the pathogens' antibacterial susceptibility.2016 年日本化疗学会、日本传染病学会和日本临床微生物学会监测委员会进行的细菌呼吸道病原体全国监测：病原体抗菌敏感性的总体情况。
J Infect Chemother. 2020 Sep;26(9):873-881. doi: 10.1016/j.jiac.2020.05.006. Epub 2020 Jun 19.
7
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.成人社区获得性肺炎诊断和治疗。美国胸科学会和美国传染病学会的官方临床实践指南。
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
8
Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.每日4次静脉注射3克舒巴坦/氨苄西林治疗日本中重度社区获得性肺炎成人患者的疗效与安全性：一项多中心、开放标签、非对照研究
J Infect Chemother. 2015 Mar;21(3):182-8. doi: 10.1016/j.jiac.2014.11.006. Epub 2014 Nov 20.
9
Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital.三级护理医院中与产超广谱β-内酰胺酶生物体相关的危险因素。
J Antimicrob Chemother. 2005 Jul;56(1):139-45. doi: 10.1093/jac/dki180. Epub 2005 May 25.
Zotero 插件